Medicaid Provider SpendingClaims paid 2018–2024 · HHS public file
Home › NC › Wilmington › NPI 1376139139
Hospital

Novant Health New Hanover Regional Medical Center LLC

Novant Health New Hanover Regional Medical Center LLC was paid $57.53M by Medicaid between Feb 2021 and Dec 2024, across 226 billing codes. Its largest line is 99284, emergency room visit (serious) — 43% of everything it billed.

33Billing provider infoNOVANT HEALTH NEW HANOVER REGIONAL MEDICAL CENTER LLC
WILMINGTON, NC 28401
33aNPI1376139139assigned 12/16/2020
33bProvider typePsychiatric Hospital Unit
28Total paid$57.53M
24GClaims865,137
24DCodes billed226
24AFirst – last monthFeb 2021 – Dec 2024
Compared with peers

Next to other Psychiatric Hospital Unit providers in North Carolina

Rank by total paid#1 of 7
Median peer was paid$295K
This provider vs. median195×

Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.

Box 24A · Dates of service

Paid by month

$0$1.0M$2.0M2018201920202021202220232024
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
YearClaimsPaid
2021203,799$10.76M
2022222,054$14.47M
2023255,721$17.39M
2024incomplete183,563$14.92M
Box 24 · Service lines

What it billed for

CodeServiceShareClaimsBene. recordsPaid
99284 Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity 43% 62,724 57,448 $24.64M
99283 Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity 19% 50,264 46,109 $10.97M
0241U Neonatal screening for hereditary disorders, genomic sequence analysis panel 5.7% 20,908 19,434 $3.27M
99285 Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life 4.2% 5,084 4,439 $2.40M
G0463 Hospital outpatient clinic visit for assessment and management of a patient 4.0% 77,034 68,181 $2.30M
96374 Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance 1.2% 15,809 14,374 $693K
99282 Emergency department visit for the evaluation and management, low to moderate severity 1.2% 5,577 5,193 $682K
71045 Radiologic examination, chest; single view 1.2% 12,930 11,950 $668K
93005 Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report 1.1% 14,603 12,839 $615K
41899 Unlisted procedure, dentoalveolar structures <1% 786 725 $508K
G0378 Hospital observation service, per hour <1% 6,132 4,444 $504K
93306 Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete <1% 851 760 $485K
214 more codes
85025 Blood count; complete (CBC), automated, and automated differential WBC count <1% 54,249 $449K
59025 Fetal non-stress test <1% 3,457 $441K
96375 Therapeutic injection; each additional sequential IV push <1% 4,989 $363K
93303 Transthoracic echocardiography for congenital cardiac anomalies, follow-up or limited study <1% 916 $335K
99213 Doctor's office visit, returning patient (routine) <1% 14,440 $314K
80048 Basic metabolic panel (calcium, ionized) <1% 36,911 $310K
J1745 Injection, infliximab, excludes biosimilar, 10 mg <1% 54 $300K
G0379 Direct admission of patient for hospital observation care <1% 4,379 $292K
74177 Computed tomography, abdomen and pelvis; with contrast material <1% 386 $283K
96361 Intravenous infusion, hydration; each additional hour <1% 5,667 $241K
80053 Comprehensive metabolic panel <1% 25,413 $237K
J3490 Unclassified drugs <1% 133,957 $227K
84443 Thyroid stimulating hormone (TSH) <1% 10,448 $224K
82306 Vitamin D; 25 hydroxy, includes fraction(s), if performed <1% 5,008 $201K
U0003 Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r <1% 2,271 $182K
88305 Level IV - Surgical pathology, gross and microscopic examination <1% 958 $181K
70450 Computed tomography, head or brain; without contrast material <1% 667 $181K
87491 Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe <1% 5,803 $179K
87591 Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe <1% 5,803 $176K
43239 Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple <1% 622 $175K
99215 Doctor's office visit, returning patient (complex) <1% 4,796 $162K
93325 <1% 1,065 $151K
87389 Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies <1% 4,817 $143K
J7030 Infusion, normal saline solution , 1000 cc <1% 10,137 $139K
36415 Collection of venous blood by venipuncture <1% 43,388 $131K
83036 Hemoglobin; glycosylated (A1C) <1% 10,047 $128K
96413 Chemotherapy administration, intravenous infusion; up to 1 hour, single or initial substance <1% 1,658 $127K
97803 <1% 1,410 $114K
87426 Infectious agent antigen detection, SARS-CoV-2 (COVID-19) <1% 2,593 $111K
93320 <1% 903 $104K
94760 <1% 6,329 $103K
87798 Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism <1% 2,506 $92K
80307 Drug test(s), presumptive, any number of drug classes; immunoassay <1% 1,312 $90K
84439 <1% 6,796 $88K
97802 <1% 829 $87K
85027 <1% 11,543 $84K
80076 <1% 9,393 $83K
81025 <1% 8,802 $74K
80061 Lipid panel <1% 3,922 $72K
81001 <1% 18,302 $71K
87651 Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe <1% 1,790 $68K
87536 <1% 1,558 $64K
96372 Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular <1% 3,379 $62K
90471 Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine <1% 5,844 $58K
94060 <1% 306 $55K
83690 <1% 6,801 $52K
88184 <1% 1,308 $51K
88175 Cytopathology, cervical or vaginal, any reporting system; collected in preservative fluid, automated thin layer <1% 1,459 $50K
87631 <1% 425 $48K
94010 <1% 962 $47K
70551 Magnetic resonance imaging, brain; without contrast material <1% 77 $47K
11042 Debridement, subcutaneous tissue (includes epidermis, dermis, and subcutaneous tissue); first 20 sq cm <1% 1,082 $45K
0002A <1% 1,001 $45K
86800 <1% 1,874 $45K
U0005 Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 <1% 1,737 $45K
Q9967 Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml <1% 1,343 $43K
86850 <1% 3,043 $43K
0001A <1% 981 $42K
87086 Culture, bacterial; quantitative colony count, urine <1% 3,884 $40K
95819 <1% 169 $40K
84403 <1% 1,049 $39K
86376 <1% 1,868 $39K
86780 <1% 1,997 $36K
83002 <1% 1,280 $34K
D0272 Bitewings - two radiographic images <1% 132 $34K
83001 <1% 1,264 $33K
J1885 Injection, ketorolac tromethamine, per 15 mg <1% 6,852 $31K
D2930 Prefabricated stainless steel crown - primary tooth <1% 111 $30K
88185 <1% 1,308 $30K
82670 <1% 885 $30K
D0220 Intraoral - periapical first radiographic image <1% 118 $30K
86762 <1% 1,727 $29K
86803 <1% 1,777 $29K
86787 <1% 1,797 $27K
D3220 Therapeutic pulpotomy (excluding final restoration) - removal of pulp coronal to the dentinocemental junction <1% 91 $27K
G0481 Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 8-14 drug class(es), including metabolite(s) if performed <1% 299 $26K
D1206 Topical application of fluoride varnish <1% 125 $26K
76801 <1% 497 $25K
95012 <1% 743 $25K
D0230 Intraoral - periapical each additional radiographic image <1% 130 $25K
82784 <1% 1,831 $24K
97161 <1% 350 $23K
83655 <1% 1,617 $23K
99214 Doctor's office visit, returning patient (more involved) <1% 923 $22K
82533 <1% 822 $21K
83525 <1% 1,169 $20K
80306 <1% 1,293 $19K
76770 <1% 129 $19K
86592 <1% 3,727 $19K
87340 <1% 1,661 $17K
83735 <1% 2,602 $17K
82728 <1% 1,040 $16K
J1439 Injection, ferric carboxymaltose, 1 mg <1% 28 $15K
99205 Prolong outpt/office vis <1% 414 $15K
J2704 Injection, propofol, 10 mg <1% 2,173 $15K
81220 CFTR (cystic fibrosis transmembrane conductance regulator) gene analysis; common variants <1% 32 $15K
94640 Pressurized or nonpressurized inhalation treatment for acute airway obstruction <1% 240 $15K
G0108 Diabetes outpatient self-management training services, individual, per 30 minutes <1% 303 $14K
95018 <1% 29 $14K
76856 Ultrasound, pelvic (nonobstetric), real time with image documentation; complete <1% 89 $13K
J7120 Ringers lactate infusion, up to 1000 cc <1% 886 $12K
85045 <1% 853 $12K
83520 <1% 626 $12K
84305 <1% 581 $11K
84484 <1% 1,077 $11K
83021 <1% 554 $11K
90472 Immunization administration, each additional vaccine (list separately) <1% 898 $11K
J2405 Injection, ondansetron hydrochloride, per 1 mg <1% 2,909 $11K
82657 <1% 377 $11K
71046 Radiologic examination, chest; 2 views <1% 104 $11K
87624 Infectious agent detection by nucleic acid; human papillomavirus (HPV), high-risk types <1% 367 $10K
84445 <1% 128 $10K
71260 Computed tomography, thorax, diagnostic; with contrast material <1% 56 $10K
87081 <1% 1,249 $10K
87635 Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe <1% 147 $10K
83516 <1% 585 $10K
76830 Ultrasound, transvaginal <1% 88 $9K
86255 <1% 568 $9K
J7050 Infusion, normal saline solution, 250 cc <1% 1,570 $9K
82950 <1% 1,434 $9K
70553 Magnetic resonance imaging, brain; without contrast material, followed by contrast material and further sequences <1% 20 $9K
81003 <1% 3,018 $8K
83540 <1% 809 $8K
G0480 Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed <1% 289 $8K
86361 <1% 157 $7K
86140 <1% 834 $7K
J1100 Injection, dexamethasone sodium phosphate, 1 mg <1% 1,070 $6K
83020 <1% 398 $6K
86003 <1% 45 $6K
90715 <1% 939 $6K
86900 <1% 1,414 $6K
81420 Fetal chromosomal aneuploidy genomic sequence analysis panel <1% 14 $6K
86901 <1% 1,415 $5K
0031A <1% 139 $5K
83550 <1% 435 $5K
J0134 Injection, acetaminophen (fresenius kabi), not therapeutically equivalent to j0131, 10 mg <1% 80 $4K
90674 <1% 930 $4K
85652 <1% 905 $4K
82248 <1% 461 $4K
83615 <1% 454 $4K
84480 <1% 159 $4K
85660 <1% 554 $3K
0071A <1% 92 $3K
D1351 Sealant - per tooth <1% 13 $3K
0072A <1% 80 $3K
J1642 Injection, heparin sodium, (heparin lock flush), per 10 units <1% 2,195 $3K
82570 <1% 404 $3K
95816 <1% 13 $3K
93242 <1% 17 $3K
87633 Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets <1% 35 $2K
93798 <1% 89 $2K
94761 <1% 57 $2K
J1170 Injection, hydromorphone, up to 4 mg <1% 342 $2K
90686 <1% 742 $2K
87661 Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe <1% 47 $2K
84156 <1% 370 $2K
81243 <1% 32 $2K
97110 Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion <1% 38 $2K
87486 <1% 35 $2K
87581 <1% 35 $2K
86364 <1% 1,224 $1K
87502 Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets <1% 16 $1K
82043 <1% 138 $1K
96415 <1% 28 $1K
84550 <1% 244 $1K
86231 <1% 1,041 $985.78
99212 Office or other outpatient visit for the evaluation and management of an established patient, straightforward <1% 51 $967.22
0124A <1% 29 $858.92
96360 Intravenous infusion, hydration; initial, 31 minutes to 1 hour <1% 13 $849.68
81329 <1% 16 $713.76
J0665 Injection, bupivicaine, not otherwise specified, 0.5 mg <1% 43 $705.58
77336 <1% 28 $625.91
84702 <1% 49 $625.78
80299 <1% 60 $578.20
85007 <1% 105 $569.88
96365 Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour <1% 15 $532.29
99204 Doctor's office visit, new patient (more involved) <1% 12 $340.56
81596 <1% 16 $320.94
76817 Ultrasound, pregnant uterus, real time with image documentation, transvaginal <1% 15 $318.43
J2930 Injection, methylprednisolone sodium succinate, up to 125 mg <1% 18 $310.59
Q0111 Wet mounts, including preparations of vaginal, cervical or skin specimens <1% 71 $301.68
J3535 Drug administered through a metered dose inhaler <1% 67 $273.58
90670 <1% 234 $259.15
J2920 Injection, methylprednisolone sodium succinate, up to 40 mg <1% 40 $238.50
J1171 Injection, hydromorphone, 0.1 mg <1% 24 $237.73
J3010 Injection, fentanyl citrate, 0.1 mg <1% 120 $222.35
82947 <1% 42 $179.56
J0690 Injection, cefazolin sodium, 500 mg <1% 45 $133.08
83992 <1% 62 $91.94
A9585 Injection, gadobutrol, 0.1 ml <1% 20 $88.51
90474 <1% 12 $86.41
82270 <1% 12 $65.02
J2250 Injection, midazolam hydrochloride, per 1 mg <1% 54 $58.29
J1644 Injection, heparin sodium, per 1000 units <1% 75 $56.38
85014 <1% 16 $41.34
85018 <1% 16 $41.34
J8540 Dexamethasone, oral, 0.25 mg <1% 105 $34.95
J8597 Antiemetic drug, oral, not otherwise specified <1% 532 $29.60
J8499 Prescription drug, oral, non chemotherapeutic, nos <1% 255 $16.95
G0008 Administration of influenza virus vaccine <1% 31 $9.35
84132 <1% 29 $6.01
91300 <1% 1,981 $5.83
Q0162 Ondansetron 1 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen <1% 14 $3.79
91307 <1% 174 $0.48
91312 0% 28 $0.00
90681 0% 24 $0.00
90633 0% 15 $0.00
A0429 Emergency ambulance ride, basic life support 0% 14 $0.00
90647 0% 87 $0.00
91303 0% 139 $0.00
A0427 Emergency ambulance ride, advanced life support 0% 68 $0.00
91301 0% 18 $0.00
90723 0% 115 $0.00
90680 0% 12 $0.00

Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.

From NPPES

Who's on the registration

Authorized officialBOVIO, ERNEST (PRESIDENT NOVANT HEALTH COASTAL REG)
Same official

Other billing entities under BOVIO, ERNEST

Full network →
ProviderLocationPaid
Novant Health New Hanover Regional Medical Center LLCWilmington, NC$2.73M
Novant Health New Hanover Regional Medical Center LLCWilmington, NC$580K
Novant Health New Hanover Regional Medical Center LLCWilmington, NC$72K
Novant Health New Hanover Regional Medical Center LLCWilmington, NC$0.00

Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.